Daiken Medical Co., Ltd.
Second Quarter (Interim) Financial Summary [Japanese GAAP] (Non-consolidated)
For the interim period of the fiscal year ending March 2027, net sales were 5,097 million yen (Year-over-Year +0.8%), operating income was 478 million yen (-29.3%), ordinary income was 474 million yen (-29.7%), and interim net income was 368 million yen (-28.0%). Full-year outlook is maintained as previously announced. Dividends plan continues through the end of the second quarter, with a full-year dividend forecast of 20 yen. Financial position remains stable with a capital adequacy ratio of 71.5% and total assets of 10,915 million yen; further details follow in the main text.
Key Figures
- Net Sales: 5,097 million yen (Year-over-Year +0.8%)
- Operating Income: 478 million yen (Year-over-Year -29.3%)
- Interim Net Income: 368 million yen (Year-over-Year -28.0%)
AI要約
Overview of Performance
For the interim period of the fiscal year ending March 2027, Daiken Medical Co., Ltd. recorded net sales of 5,097 million yen (Year-over-Year +0.8%). Despite a slight increase in revenue, operating income declined significantly to 478 million yen (-29.3%) due to rising material costs and higher personnel expenses. Ordinary income was 474 million yen (-29.7%), and interim net income was 368 million yen (-28.0%), with key profit indicators falling below the prior-year period.
Financial Position and Dividends
Total assets are approximately 10,915 million yen, net assets are 7,829 million yen, and the capital adequacy ratio remains at 71.5%, maintaining a stable financial base. There is no revision to the recently announced dividend forecast; the company continues to plan an annual dividend of 20 yen, including a year-end dividend of 11 yen.
Daiken Medical Co., Ltd.
Company overview · Stock price · Financial data · All IR
